Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment

IMPORTANCE: The goal of preclinical Alzheimer disease (AD) clinical trials is to move diagnosis and treatment to presymptomatic stages, which will require biomarker testing and disclosure. OBJECTIVE: To assess the short-term psychological outcomes of disclosing amyloid positron emission tomography r...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :JAMA Neurol
Главные авторы: Grill, Joshua D., Raman, Rema, Ernstrom, Karin, Sultzer, David L., Burns, Jeffrey M., Donohue, Michael C., Johnson, Keith A., Aisen, Paul S., Sperling, Reisa A., Karlawish, Jason
Формат: Artigo
Язык:Inglês
Опубликовано: American Medical Association 2020
Предметы:
Original Investigation
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7418046/
https://ncbi.nlm.nih.gov/pubmed/32777010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2020.2734
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы